<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome is characterized by arterial and <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> including hepatic veins </plain></SENT>
<SENT sid="1" pm="."><plain>Although transjugular intrahepatic portosystemic shunt or liver transplantation have been considered for <z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo>, treatment options for patients with <z:e sem="disease" ids="C0001168" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">complete obstruction</z:e> of three hepatic veins including the junction with the inferior vena cava are limited </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a 27-year-old female, who suffered thrombotic obliteration of hepatic veins including the portion confluent with the inferior vena cava (<z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo>) associated with marked <z:hpo ids='HP_0001541'>ascites</z:hpo> and <z:hpo ids='HP_0001410'>liver dysfunction</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Transjugular intrahepatic portosystemic shunt using a Wall-stent (10 mm in diameter) between inferior vena cava and intrahepatic portal vein was performed </plain></SENT>
<SENT sid="4" pm="."><plain>Intrastent coagulation and recurrence of <z:mp ids='MP_0005048'>thrombosis</z:mp> were prevented by combination therapy with <z:chebi fb="0" ids="32301">warfarin potassium</z:chebi> and <z:chebi fb="0" ids="9589">ticlopidine hydrochloride</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>These treatments induced loss of <z:hpo ids='HP_0001541'>ascites</z:hpo> and improvement of liver function, and she has been able to resume daily life </plain></SENT>
<SENT sid="6" pm="."><plain>The portosystemic shunt described above in addition to combination therapy with <z:chebi fb="0" ids="32301">warfarin potassium</z:chebi> and <z:chebi fb="0" ids="9589">ticlopidine hydrochloride</z:chebi> appeared to be one of the options for treating <z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo> associated with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
</text></document>